Abstract
The current SARS-COV-2 epidemic is associated with nearly 1 million estimated deaths and responsible for multiple disturbances around the world, including the overload of health care systems. The timely prediction of the medical needs of infected individuals enables a better and quicker care provision for the necessary cases, supporting the management of available resources.
This work ascertains the predictability of medical needs (as hospitalization, respiratory support, and admission to intensive care units) and the survivability of individuals testing SARS-CoV-2 positive considering a cohort with all infected individuals in Portugal as per June 30, 2020. Predictions are performed at the various stages of a patient’s cycle, namely: pre-hospitalization (testing time), pos-hospitalization, and pos-intensive care. A thorough optimization of state-of-the-art predictors is undertaken to assess the ability to anticipate medical needs and infection outcomes using demographic and comorbidity variables, as well as onset date of symptoms, test and hospitalization.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors thank Direção Geral da Saúde (DGS) for providing data. This work was further supported by Fundação para a Ciência e a Tecnologia (FCT) under the LAETA (UIDB/50021/2020), IPOscore (DSAIPA/DS/0042/2018), Data2Help (DSAIPA/AI/0044/2018) and iCare4U (PTDC/EME-SIS/31474/2017) projects, the contract CEECIND/01399/2017 and by FCT/MCTES funds for the Associate Laboratory for Green Chemistry LAQV (UIDB/50006/2020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
− Direção Geral da Saúde (DGS) - Ethical Committee of the FCT-NOVA University
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The COVID-19 dataset was provided by DGS.
